Immunotherapy with rilvegostomig plus chemotherapy for advanced stomach cancer
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This trial tests whether a new immunotherapy (rilvegostomig) combined with chemotherapy can help people with advanced stomach or gastroesophageal junction cancer. The study aims to understand how the treatment affects the immune system in the tumor and throughout the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread to other parts of the body.
- Your cancer has not been treated with systemic therapy (like chemotherapy or immunotherapy) for advanced disease.
- Your tumor is HER2-negative (no HER2 protein) and has PD-L1 expression with CPS ≥ 1.
- Your doctor confirms adequate organ function and performance status (able to do daily activities).
- You have a tumor lesion that can be biopsied for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer who have not had prior treatment. It aims to see if this combination can shrink tumors and help people live longer.
This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.
This study tests a new investigational drug, rilvegostomig, given as an injection under the skin. It is for people with advanced solid tumors that have not responded to or have progressed after standard treatments. The goal is to see how the drug behaves in the body and to assess its safety.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests a combination of two treatments: an immunotherapy drug (pembrolizumab, which helps your immune system fight cancer) and chemotherapy (FLOT) for advanced stomach or esophageal junction cancer. The goal is to see if this combination is safe and works better than standard care.
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
Hear when a new Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.